Clinical trial
A Prospective, Multicenter, Randomized, Open-label, Active-controlled, 2-parallel Group, Phase III Study to Compare Efficacy and Safety of Masitinib at 7.5 mg/kg/Day to Imatinib at 400 or 600 mg in Treatment of Patients With Gastro-intestinal Stromal Tumor in First Line Medical Treatment
NCT00812240 is registered in ClinicalTrials.gov with AB Science as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Prospective, Multicenter, Randomized, Open-label, Active-controlled, 2-parallel Group, Phase III Study to Compare Efficacy and Safety of Masitinib at 7.5 mg/kg/Day to Imatinib at 400 or 600 mg in Treatment of Patients With Gastro-intestinal Stromal Tumor in First Line Medical Treatment
- Lead sponsor
- AB Science
- Phase
- Phase 3
- Overall status
- Terminated
- Start date
- January 31, 2009
- Completion date
- July 31, 2018
- Enrollment
- 335 (actual)
- Sites
- 41
Conditions
As the registry lists them; a condition with its own page is linked.